Home/Pipeline/BO-212

BO-212

Not Disclosed

ResearchActive

Key Facts

Indication

Not Disclosed

Phase

Research

Status

Active

Company

Highlight Therapeutics

About Highlight Therapeutics

Highlight Therapeutics is a clinical-stage biotech pioneering intra-lesional RNA therapies to activate the immune system against cancer, with a primary focus on skin cancers. The company's lead asset, BO-112, is in Phase 2b development for basal cell carcinoma (BCC) and has shown promise in combination with anti-PD-1 agents. Leveraging a unique approach to convert immunologically 'cold' tumors 'hot,' Highlight aims to address significant unmet needs in dermato-oncology, a field with a large and growing patient population. The company operates as a private, pre-revenue entity advancing its pipeline through clinical trials.

View full company profile

Therapeutic Areas

Dermato-oncology Oncology

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
SRSD101	Sirius Therapeutics	Phase 1	Active